ABSTRACT
INTRODUCTION
After androgen escape, the prostate tumor cell proliferation becomes independent of normal growth control mechanisms. As Ca 2+ homeostasis is imperative in growth regulation, it is important to understand how various growth factors, neurotransmitters and hormones, known to control physiological and pathological cell proliferation, participate in the maintenance of intracellular Ca 2+ homeostasis. Although the nature of these agonists has yet to be wellestablished during prostate cancer progression, they invariably induce a Ca 2+ entry called "agonist-induced Ca 2+ entry" (ACE) (4, 6, 27, 30) .
Despite α1-adrenoceptor (α1-AR) antagonists being already widely used for the clinical treatment of benign prostate hyperplasia (BPH) (5), the exact role of α1-AR-coupled signaling pathway in prostate cancer growth control remains unclear. Clinical studies have
shown that α1-AR antagonists induce apoptosis in human prostate cancer epithelial and smooth muscle cells without affecting the cellular proliferation (20) , in a way that seems to be independent of their effects on α1-AR (3, 19) . In our previous study, using an androgendependent LNCaP (Lymph Node Carcinoma of the Prostate) cell line (17) as experimental model, we have demonstrated that α1-AR stimulation activates non-specific cationic channels leading to ACE (38).
Interestingly, we have also previously shown that in contrast to the stimulatory role of α1-ARs on prostate cancer cell growth, metabotropic purinergic receptors (P2Y-R) are involved in the growth arrest of DU-145 human prostate cancer cells (44). Such divergent effects of two receptors on cell proliferation are surprising, since both α1-AR and P2Y-R are known to be coupled to the common phospholipase C (PLC) catalyzed inositol phospholipids breakdown signaling pathway, via which α1-agonists and extracellular ATP are capable of inducing apparently similar increases in intracellular free Ca 2+ ([Ca 2+ ] i ) (22, 25) . The opposite end effects on cell proliferation can only be explained if the ACE controlled by each receptor utilizes different but still undetermined Ca
2+
-permeable membrane channels ultimately destined to target various intracellular effectors. Currently, the members of the extensively studied transient TRP-channel family, especially TRPC subfamily (7) , are considered as the most promising candidates as underlying various types of ACE, including ACE involved in proliferative cell activity (13, 14, 18, 26) . However, the involvement of TRPs in mediating ACE, as well as the mechanisms of translation of generated Ca 2+ signal into proliferative activity of prostate cancer cells, is far from being understood.
The expression of genes involved in cell proliferation and cell death is regulated by nuclear transcriptional factors. NFAT (Nuclear Factor of Activated T cells) proteins represent a family of Ca
-dependent transcription factors (8) whose activity is regulated by Ca 2+ /calmodulin-dependent protein phosphatase, calcineurin (8) . Another ubiquitously expressed transcription factor is represented by the NF-kB (nuclear factor kappa B) family (21) which is known to be dependent on Ca 2+ homeostasis, especially on the filling status of Ca 2+ endoplasmic reticulum (ER) stores (7) .
In the present study, we asked firstly whether the divergent effects on prostate cancer epithelial cell proliferation of ACE triggered by distinct membrane receptors via common signaling cascade, could be explained by different coupling efficiencies of Ca 2+ entry pathways involved in either NFAT or NF-kB activation. Secondly, we wished to ascertain, if the latter were so, what type of membrane channels underlie these pathways. To this end, we used primary cultures of human prostate cancer epithelial (hPCE) cells established from resection specimens, which is much more relevant from practical perspectives than using cell lines. This allowed us to show for the first time that α1-AR stimulation enhances hPCE cells proliferation via a store-independent Ca 2+ entry resulting in NFAT activation. We also show that α1-AR-stimulated Ca 2+ entry mostly relies on TRPC6, which is a TRP-channel family member, and that TRPC6 antisense knockout exerts effects similar to those of pharmacological α1-AR inhibition, i.e. suppression of ACE and consequent termination of hPCE cells proliferation. Furthermore, chronic hPCE cell treatment with α1-agonists enhances TRPC6 protein expression. In contrast, ACE associated with P2Y-R stimulation by extracellular ATP and related growth arrest involves neither TRPC6 channels activation nor NFAT translocation. Our findings demonstrate that the α1-AR-dependent Ca 2+ signaling which promotes hPCE cell proliferation specifically requires the activation of TRPC6 channels coupled to NFAT and thereby suggest TRPC6 as a novel potential therapeutic target for controlling prostate cancer cell proliferation.
MATERIALS AND METHODS
Primary culture. Human prostate specimens were mechanically dissociated and then were cultivated in KSF medium (GIBCO-BRL), supplemented with 50 µg/ml bovine pituitary extract and 50 ng/ml EGF to specifically select epithelial cells. Each samples were analyzed by immunofluorescence staining to verify the epithelial markers expression (cytokeratin 14 and 18, (40), data not shown). The culture medium also contained 50000 IU/L penicillin and 50 mg/L streptomycin. Cells were routinely grown in 50 ml flasks (Nunc, Poly-labo) and kept at 37°C in a humidified incubator in an air/CO 2 (95/5%) atmosphere. For electrophysiology and calcium imagery experiments, the cells were subcultured in Petri dishes (Nunc) and used after 3 to 6 days. Each primary culture was only maintained for two weeks to prevent the lost of their differentiated phenotype.
We used specimens from 4 localized prostate cancers of Gleason score 8-10, prostatespecific antigen (PSA) level of ≥ 4.0 ng/ml and clinical tumor stage T2, from patients having undergone a radical prostatectomy. The cases were specifically selected on the criteria that the tumors were non-metastatic, and had no history of chemo-and/or anti-androgen therapy.
Because of this, we believe that prostate cancer epithelial cells derived from the specimens used most likely represented androgen-dependent population. The presence of normal epithelial cells was highly unlikely, since cancerous nature of the specimens was independently confirmed by histological and anatomo-pathological analysis. All experimentations on patients tissues were performed according to the medical ethics under the agreement number "CP 01/33" delivered by the "Comité Consultatif de Protection des Personnes dans la Recherche Biomédicale de Lille" (CCPPRB).
Calcium imaging. [Ca

2+
] i was measured using fura-2 (the detailed procedure has been described previously (15, 33) RT-PCR analysis. Total RNA from the hPCE cells was isolated as previously detailed (38). For the PCR reaction, specific sense and antisense primers were designed, based on GenBank hTRP sequences, using Genejockey II (Biosoft, Cambridge, UK) as listed in Table   1 . In order to further identify the PCR-amplified products, each PCR band was extracted from the agarose gel and then subjected either to the restriction analysis using the specifique enzymes for each amplified fragment (for PCR products presented in Fig. 3 ) or subcloned in TA-cloning vector (Invitrogen) followed by the sequencing analysis (for PCR products presented, data not shown).
The sequences of selected oligonucleotides used as RT-PCR primers or as sense and antisenses are presented in Table I .
Transient transfection. For antisense assays, the sense (control) and antisense oligonucleotides (Eurogentec) targeted against each TRPC (TRPC1, TRPC3, TRPC4 and TRPC6) were designed at the initiating ATG codon level (see Table I for sequences). The hPCE cells treated for up to 72h with either 0.5 µmol/L phosphorothioate antisense oligodeoxynucleotides (ODNs) and 2.5 µM cytofectin (GS 3815 to DOPE at a 2:1 molar ration, unsized) (Eurogentec) or sense ODNs by adding them directly to the culture medium.
The ODNs transfection procedures were as detailed previously (42). 2B, n=63 ).
The inclusion of the IP 3 -receptor antagonist heparin (0.1 g/L) in the intracellular pipette solution used in the whole-cell patch-clamp experiments had no effect on the ability of PHE to activate membrane current (Fig. 2C ), but totally abrogated ATP-evoked current (Fig. 2D) (n=5-11). PHE and ATP both activated inwardly rectifying membrane currents: I-V relationships for both currents are presented in inset of Fig.2C and 2D . PHE-evoked current reached its full amplitude in about 2.0±0.7 min and its average density was 11±1.5 pA/pF at V m =-100 mV (n=11) whereas the average density of ATP-induced current, which reached its full amplitude in about 1.5±0.8 min, was 1.3±0.6 pA/pF at V m =-100 mV (n=5).
We also compared the effects of such widely used inhibitors of store-dependent and ] i elevation following Ca 2+ readdition (as presented in Fig. 1E ) in the event of ATP. As one can see in Fig. 2E (n=95-102) , all agents except for 2-APB at low (10 µmol/L) concentration, strongly inhibited the ATPinduced response. They exerted virtually no effect on the PHE-induced one except for the SK&F 96365, which blocked the response to PHE by about 50%. Such divergent sensitivity is again consistent with the substantial role played by store-dependent processes in ATP actions, but not in those of PHE, since all the agents used are generally known to be more specific to store-operated channels than to other types of cationic channels. Moreover, although 2-APB effects can block both IP 3 receptors and SOCs (11), its ability to stimulate ATP response at a low concentration (10 µmol/L) and to inhibit it at a high concentration (100 µmol/L, see Thus, our results unequivocally demonstrate that in hPCE cells, ATP-stimulated P2Y-Rcoupled Ca 2+ signaling involves Ca 2+ entry via store-operated membrane channels, whereas PHE-stimulated α1-AR-coupled Ca 2+ signaling involves Ca 2+ entry via store-independent DAG-gated Ca 2+ permeable cationic channels.
TRPC channel expression in human prostate cancer epithelial cells. In the attempt to define the molecular identity of the channels underlying PHE-and ATP-induced ACE, using specific primers (Table I ) and the RT-PCR technique, we first studied the expression of the mRNA of the human isoforms of the TRPCs (TRPC1, TRPC3, TRPC4 and TRPC6) in hPCE cells. In the first set of experiments, the specific primers were designed to amplify a portion of the N-terminal sequence surrounding the initiating codon ATG of each TRPC member (Fig.   3A, D) . In the second set of experiments, specific primers were designed to identify the TRPC4 and TRPC6 splice variants isoforms (Fig. 3E, F) , except for the TRPC1 where the Nterminal primers allow us to identify the splice variants. Fig. 3 shows the expression of the transcripts for the TRPC1A splice variant (Fig. 3A) , and the PCR products of the expected sizes for the TRPC3 (Fig. 3B) , TRPC4 (Fig. 3C ) and TRPC6 (Fig. 3D ) in hPCE cells. The study of the splice variants isoforms (Fig. 3E, F) shows that the TRPC4β and TRPC6γ spliced isoforms were expressed in hPCE cells in addition to unspliced forms of TRPC4 and TRPC6. Thus, these data indicate that endogenous TRPC1 and TRPC4 channels are exclusively involved in ATP-stimulated store-dependent type Ca 2+ entry, whereas TRPC6 is the primary DAG-gated channel mediating PHE-stimulated store-independent Ca 2+ entry involved in oscillatory-type Ca 2+ signaling in hPCE cells. Endogenous TRPC3 is probably plays an equal role in both store-dependent and store-independent Ca 2+ influx pathways.
Alpha1-AR agonist phenylephrine, but not ATP promotes hPCE cell proliferation via
TRPC6 up-regulation. In our previous studies we have shown that PHE promotes the proliferation of androgen-dependent prostate cancer LNCaP cells via the mechanism involving Ca 2+ influx (38, 44), whereas extracellular ATP causes the growth arrest of androgen-independent prostate cancer DU-145, by affecting store-dependent processes (38, 44). Therefore, it was natural to examine how the two agonists influence the proliferation of primary hPCE cells as well.
Consistent with our observations of other prostate cancer cell types, two-day-treatments of primary hPCE cells with PHE (10 µmol/L) enhanced their proliferation by 37.3±2.0%, whereas the same period of ATP (100 µmol/L) treatment inhibited cell proliferation by 61.6±1.6% (Fig. 4B) . Specific effect of the agonists on cell's proliferation was further confirmed by assaying the expression of two cell-cycle regulators, cyclin-dependent kinase 4
(CDK4) and cyclin-dependent kinase inhibitor p27 (35) , by immunofluorescent staining with FITS-conjugated anti-CDK4 and anti-p27 antibodies. Inspection of the images presented in Fig. 4C shows that PHE treatment resulted in the upregulation of CDK4 expression and downregulation of p27 expression in contrast to ATP, whose action on the expression of these cell-cycle regulators was exactly opposite. These data permitted us to conclude that the effects of PHE and ATP on cells count were indeed related to cell proliferation and growth arrest, respectively.
To prove the critical involvement of TRPC6 in growth-regulating properties of α1-AR and P2Y-R agonists, we used hPCE cells subjected to TRPC6 hybrid depletion. In the absence of agonists, hPCE cells demonstrate similar proliferation activity irrespective of whether they were treated with TRPC6 sense (TRPC6/s) or antisense (TRPC6/as) oligonucleotides ( Moreover, semi-quantitative Western blot analysis for possible changes in the expression of TRPC6 involved in PHE-induced Ca 2+ signaling, which is likely to underlie growth-regulating effects, have revealed a ∼3-fold up-regulation of TRPC6 expression in response to PHE-treatment (Fig. 4D) .
Altogether, these results point to the key role of TRPC6 in PHE growth-regulating functions.
Proliferation promoting effects of α1-AR agonists involve NFAT activation. To determine which transcription factor(s) mediate opposing effects of α1-AR and P2Y-R agonists on primary hPCE cells growth, we used cells transiently transfected with the pCIS-CK plasmid containing an insert of luciferase reporter gene driven by either synthetic NFATor NF-kB-dependent promoter (see Methods). agonist produced a significant change in NF-kB-dependent luciferase expression (Fig. 5B) .
Moreover, PHE-induced increase in cell proliferation was specifically related to the increased NFAT activity, as blocking calcineurin by cyclosporin A (100 nmol/L) or FK506 (10 µmol/L) thereby impeding nuclear NFAT translocation, prevented the ability of PHE to induce cell proliferation without affecting the ATP-induced growth arrest (Fig. 5C ). Thus, α1-ARmediated stimulation of hPCE cell proliferation mainly occurs via NFAT activation.
DISCUSSION
In the present work, we have focused on elucidating the specifics of Ca 2+ signaling involved in the opposing effects on human prostate cancer epithelial cell proliferation of α1-adrenoceptor and P2Y-purinergic receptor agonists, and report on three major findings: 1) α1- Thus, it seems to be proven that α1-AR-coupled signaling is associated with the enhancement of hPCE cell proliferation, whereas P2Y-R signaling brings about a cessation of proliferative activity. We have shown that despite being initiated by the common PLC- influx (Fig. 6) . Currently, it is well-known that IP 3 has a short half-life within the cell and that the diffusion of locally produced IP 3 is rate limiting (1, 28, 32) . The only determinants of IP 3 spatial range of action are its lifetime and diffusion constant in cytoplasm. However, little is known about assessing these variables in single cell: there are rather used computational models but no indicator is available that would allow IP 3 to be visualized (45). Similar difficulties appear to study the intracellular signaling of DAG. The carbon-11 labeled DAG was proposed to evaluate its intracellular signaling but its use needs further investigations (12) . Due to these technical limitations, adressing the question of such divergence between α1-AR-coupled and P2Y-R signaling appears unrealistic.
Recent data suggest that oscillatory [Ca 2+ ] i activity may be especially suited to the specificity of Ca 2+ signaling (9) , as the possibility of amplitude and frequency signal encoding permits distinct effectors to be targeted. Our data on selective proliferation promoting α1 agonist action via the induction of Ca 2+ oscillation in hPCE cells, are consistent with this notion. Moreover, the fact that these oscillations translate into enhanced hPCE cell proliferation, via the activation of the Ca On the other hand, the suppressive effects of ATP-mediated P2Y-purinergic receptor stimulation on hPCE cell proliferation, via the induction of store-dependent Ca 2+ signaling, are generally consistent with the critical role of the ER Ca 2+ store content and store-operated Ca 2+ channels in the regulation of prostate cancer cell apoptosis, as shown in our previous works (33, 43) . Indeed, persistent activation of P2Y-purinergic receptors may cause chronic underfilling of ER Ca 2+ store and an adaptive decrease in SOCE, which although may not be sufficient to induce apoptosis (33, 43) , but sufficient to exert anti-proliferative effects (44).
TRP members involved in agonist-stimulated Ca 2+ entry in human prostate cancer epithelial cells. Our results also highlight the importance of Ca 2+ entry pathways in the discrimination of the signaling via α1-adrenergic and P2Y-purinergic receptors in hPCE cells.
Indeed, as we show, the α1-AR agonist, PHE, as well as the DAG analog, OAG, activate Ca 2+ entry mainly via the TRPC6 channel, whereas store-dependent type Ca 2+ entry activated by ATP, predominantly involves TRPC1 and TRPC4 channels.
The literature ascribing various TRPC members to the DAG-gated or SOC type is quite conflicting and controversial, suggesting that each member, depending on cell type, the level of its expression and the presence of other members, may exhibit preferential DAGdependent, store-dependent or even dual modes of activation (2, 29, 39). Therefore, a thorough assessment of the contribution of each particular TRP in the creation of the specific type of Ca 2+ entry pathway is required in every case. In this respect, the information available on prostate cancer cell is very limited. So far, our own data obtained in the prostatic LNCaP cell line only suggests that TRPC1 and the member of the "vanilloid" TRP subfamily, TRPV6, are predominantly involved in SOC formation (42), which agrees closely with the TRPC1 role in ATP-induced store-dependent type Ca 2+ entry established above. Moreover, TRPC1 is one of those channels most involved in store-operated Ca 2+ entry in general (2).
Another TRPC member, TRPC4, which we also identified as essentially contributing to ATPinduced store-dependent type Ca 2+ entry in hPCE cells, has been demonstrated both in the SOCE and in other cell models (29).
Although the existence of a direct DAG-gated activation mode for heterologously expressed TRPC6 is well established (10, 16, 39) , when it comes to DAG-gated TRPCs are, our study is the first to identify endogenous TRPC6 as a primary determinant in physiologically relevant agonist-induced Ca 2+ entry operating on the direct DAG gating mechanism in cells of prostate origin, Moreover, we not only uncover the TRPC6 involvement in the generation of PHE-induced Ca 2+ oscillations in hPCE cells by providing Ca 2+ entry, but also demonstrate the likely role of this channel in the enhancement of the proproliferating effects of α1-AR agonists, since chronic exposure to PHE causes TRPC6 overexpression. It is also quite plausible that promotion of proliferation in response to α1-ARs stimulation may result not only from the higher coupling efficiency of Ca 2+ oscillations to NFAT activation, but also from the spatial co-localization of TRPC6 with the machinery of Ca 2+ -dependent NFAT activation.
In general, the role of TRP members in proliferation activity has been best studied for smooth muscle cells. Interestingly, the results of these studies point to both TRPC1 and TRPC6 as important determinants in the promotion of pulmonary vascular smooth muscle cell proliferation (36, 46) . However, the underlying mechanisms seem to involve the enhancement of store-operated Ca 2+ influx only, including both TRPCs channels. 
Potential clinical implications.
